Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESIRE MS: Anti-CD20 Maintenance vs De-Escalation in RRMS
NCT07189325Phase 3Recruiting
- Sponsor
- CHU Montpellier
- Start
- Jun 2026
- Primary completion
- Jun 2031
- Modality
- Cytokines & Interferons, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by CHU Montpellier. Primary endpoints: Relapse at 36 months and New/enlarged MRI lesions at 36 months. Started Jun 2026; status: recruiting.
02
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT07189325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07189325.